Quest Diagnostics (DGX) Net Income towards Common Stockholders (2009 - 2026)

Quest Diagnostics has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting -$40.0 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$40.0 million, down 121.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $637.0 million (down 18.33% YoY), and the FY2025 annual result was $968.0 million, up 11.65% from the prior year.
• Net Income towards Common Stockholders came in at -$40.0 million for Q1 2026 at Quest Diagnostics, down from $213.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $304.0 million in Q1 2022 to a low of -$40.0 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is $199.0 million (2024), against an average of $184.3 million.
• Across the five-year window, Net Income towards Common Stockholders surged 113.16% in 2023 and tumbled 121.74% in 2026, its largest moves.
• Quest Diagnostics' Net Income towards Common Stockholders stood at $76.0 million in 2022, then soared by 113.16% to $162.0 million in 2023, then grew by 20.99% to $196.0 million in 2024, then climbed by 8.67% to $213.0 million in 2025, then sank by 118.78% to -$40.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$40.0 million (Q1 2026), $213.0 million (Q4 2025), and $214.0 million (Q3 2025), per Business Quant data.